SGLT2 inhibitor

Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a class of medications primarily used to treat type 2 diabetes by preventing the kidneys from reabsorbing glucose, leading to its excretion through urine. These inhibitors not only help in lowering blood sugar levels but also offer additional benefits such as reducing the risk of heart failure and kidney disease in diabetic patients. SGLT2 inhibitors are particularly beneficial for individuals with type 2 diabetes who are seeking to manage their blood sugar levels and reduce associated cardiovascular and renal risks.

SGLT2 inhibitor was discovered on May 3rd 2023 and it currently has a search volume of 90.5K with a growth of +300%.